Transtympanic STS Against Cisplatin-induced SNHL: the SOUND Trial
NCT ID: NCT07281508
Last Updated: 2025-12-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
100 participants
INTERVENTIONAL
2025-08-14
2030-03-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Researchers will compare the ear treated with STS gel to the untreated ear within the same patient to see if STS prevents hearing loss.
Participants will:
1. Receive STS gel injections into the middle ear of one ear (randomized) within 3 hours before each cisplatin infusion (3-7 injections per patient).
2. Undergo hearing tests at baseline and 2-4 months after the last cisplatin treatment.
3. Complete questionnaires about hearing and tinnitus at baseline and 2-4 months after treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss
NCT01451853
Otoprotection With SPI-1005 for Prevention of Temporary Auditory Threshold Shift
NCT01444846
Transtympanic Ringer's Lactate for the Prevention of Cisplatin Ototoxicity
NCT01108601
Efficacy and Safety of AC102 Compared to Steroids in Adults With Idiopathic Sudden Sensorineural Hearing Loss (ISSNHL)
NCT05776459
Antioxidation Medication for Noise-induced Hearing Loss
NCT00552786
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study is an investigator-initiated randomized controlled multicenter phase III trial. Patient accrual and treatment (treatment and hearing analysis will take 22 weeks per patient) will start in 2025 and will be completed in 2028. Afterwards, the patients will have a routine follow-up for a median of 2 years to collect necessary survival data (2025-2030).
Trial population:
A hundred patients with solid head and neck malignancies who are treated with ≥ 200 mg/m2 cisplatin will be included. To be eligible for participation, patients must be 18 years or older. Study participation is not possible if more than 30 gray radiotherapy is applied to the inner ear, asymmetric hearing loss or more than 40 dB hearing loss is detected before start of treatment, known hypersensitivity to STS injections, and/or if patients have ear conditions that prevent middle ear injections from being administered properly.
Interventions:
Patients will be treated with an STS injection in one ear and no treatment in the contralateral ear. The ear to be treated with STS gel will be determined by randomization. The hearing of the treated ear will then be compared with the untreated ear. The audiometrist who conducts the hearing test will not know which ear has been treated with sodium thiosulfate. Hence, the design of this trial takes advantage of the fact that every patient has two ears, and offers the unique concept of having a randomized controlled comparison of platinum-induced hearing loss of the treated versus the untreated ear within individual patients. This results in the advantage that during the analysis of the results differences between patients are eliminated. The STS gel will be injected into the middle ear within three hours before each cisplatin infusion (range 3-7 injections per patient) into one ear, the other ear will be left untreated. Hearing tests will be conducted at baseline (before the first cisplatin therapy) and 3 months (range 2 - 4) after the last cisplatin infusion. Questionnaires will be filled in to document hearing-related complaints at baseline and 3 months (range 2 - 4) after the last cisplatin treatment. For the survival analysis on a median of 1 and 2 years after treatment, survival data will be collected from the patient's medical records. These data will be compared to similar patients from historical data. In a pilot of 10 patients in the LUMC vestibular testing will be performed at baseline and 6 weeks after the last cisplatin infusion.
Ethical considerations relating to the clinical trial including the expected benefit to the individual subject or group of patients represented by the trial subjects as well as the nature and extent of burden and risks:
Based on the results of our successfully completed phase I study, we expect that 30-50% of patients will experience a noticeable difference between the STS-treated and untreated ear (2). The STS injections in the middle ear carry small risk. Our phase 1 study has shown that administrations of sodium thiosulfate are safe. The possible risks/side effects of the injections are pain, temporary fullness in the ear, temporary dizziness, and temporary decreased hearing. There is also a very small (\<1%) risk of permanent perforation of the eardrum. The injections will be given before every cisplatin treatment because sodium thiosulfate remains available in the middle and inner ear for only a temporary period. The METC does not agree with the use of a placebo control, as the risk of a complication (albeit small) is not acceptable. The current standard of care is 'no treatment' and the audiogram provides a sufficiently objective measurement. Therefore, the study design is changed to a non-placebo randomised controlled trial and only the audiometrist is blinded.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Transtympanic sodium thiosulphate (STS) 0.1M/0,5% hyaluronate
One ear of a patient: The transtympanic sodium thiosulphate is administered into one ear of a patient. The intervention takes place within 3 hours before each cisplatin course. The intervention takes place 3 to 7 times, depending on the cisplatin schedule
Transtympanic sodium thiosulphate (STS) 0.1M/0,5% hyaluronate
The transtympanic injection gel is composed of the following components:
* Sodium Thiosulfate 250mg/mL, 10mL for injection (STS)
* BiolevoxTM HA 2,2%, 2mL, pre-filled syringe for intraarticular injection (HYA)
* Sterile Phosphate-buffered Sodium Chloride, 500mL (PBS)
Untreated ear
The other ear of the same patient is left untreated
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Transtympanic sodium thiosulphate (STS) 0.1M/0,5% hyaluronate
The transtympanic injection gel is composed of the following components:
* Sodium Thiosulfate 250mg/mL, 10mL for injection (STS)
* BiolevoxTM HA 2,2%, 2mL, pre-filled syringe for intraarticular injection (HYA)
* Sterile Phosphate-buffered Sodium Chloride, 500mL (PBS)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Treatment with high-dose cisplatin (cumulative dose ≥ 200mg/m2) of maximum 7 cycles
* Able and willing to give written informed consent;
* WHO performance status of 0, 1 or 2;
* Age older than 18 years.
Exclusion Criteria
* Baseline hearing: more than 40 dB SNHL at PTA 1-2-4 kHz (in one or both ears)
* A planned radiation dose of \> 30 Gy to the cochlea (8);
* Known hypersensitivity to STS-containing HYA gel formulation;
* Any condition that would, according to the investigator's judgement, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures;
* Otologic pathology that hampers the transtympanically applied STS gel to diffuse through the round window, e.g. otosclerosis, a narrow ear canal, otitis media with effusion.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Netherlands Cancer Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lotje Zuur, Prof. Dr.
Role: PRINCIPAL_INVESTIGATOR
AVL
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Antoni van Leeuwenhoek
Amsterdam, North Holland, Netherlands
Leiden University Medical Center
Leiden, South Holland, Netherlands
Erasmus Universitair Medisch Centrum Rotterdam
Rotterdam, South Holland, Netherlands
University Medical Center Utrecht
Utrecht, Utrecht, Netherlands
Stichting Radboud University Medical Center
Nijmegen, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M21STS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.